Skip to content

Vitamin A Value of Spirulina Carotenoids in Humans

Vitamin A Value of Spirulina Carotenoids in Humans

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00680277
Enrollment
20
Registered
2008-05-20
Start date
2004-04-30
Completion date
2008-12-31
Last updated
2017-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrinsically Labeled Spirulina

Keywords

spirulina, carotenoids

Brief summary

The goal of this protocol is to determine the vitamin A value (equivalence) of spirulina. The investigation will use intrinsically deuterium labeled spirulina and an isotope vitamin A reference dose, 13C10- retinyl acetate (13C10 RAc), in males (n=20). Up to 45 blood samples (10 ml/sample) will be collected from each subject over a two-month period to evaluate the bioavailability and bioconversion of spirulina ß-carotene to vitamin A.

Detailed description

By utilizing novel stable isotope dilution techniques recently developed in our laboratory, we will trace deuterium labeled ß-carotene in intrinsically labeled spirulina, which is harvested from a hydroponic system. In the mean time, we will track 13C10 labeled vitamin A in humans. In this way we will determine absorption of ß-carotene from spirulina matrix and the conversion of the spirulina ß-Carotene to retinol. This will enable us quantitatively determine the vitamin A equivalence of spirulina. The specific aims of this study are: 1. To determine labeled ß-C blood response kinetics following an acute dose of intrinsically labeled spirulina; 2. To determine labeled retinol blood response from the intrinsically labeled spirulina; 3. To determine 13C10 retinol blood response from the isotope reference material 13C10 retinyl acetate; 4. To determine s spirulina-vitamin A equivalence.

Interventions

DIETARY_SUPPLEMENTspirulina ß-carotene

an acute dose of spirulina up to 5 g

Sponsors

Nestlé Foundation
CollaboratorOTHER
Tufts University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteer

Exclusion criteria

* Not has GI track problems * Any medical condition that will affect the intestinal absorption

Design outcomes

Primary

MeasureTime frame
The enrichment of spirulina ß-carotene and its cleavage product vitamin A were tracked after taken the oral dose of intrinsically labeled spirulina.51 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026